Al's Comment:
This is a very important trial - hopefully it will allow GBM patients who happen to have the "bad" markers to do as well (or better) than the current standard of care does with GBM patients who have the "good" markers!
Posted on: 05/08/2017
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)
www.prnewswire.com/news-releases/delmar-presents-new-mechanism-of-action-data-for-its-lead-agent-val-083-in-temozolomide-resistant-glioblastoma-multiforme-gbm-at-the-world-federation-of-neuro-oncology-societies-wfnos-300452896.html
Click HERE to return to brain tumor news headlines.
